Harvest Fund Management Co. Ltd Grows Stock Position in Eli Lilly and Company (NYSE:LLY)

Harvest Fund Management Co. Ltd raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 9,204 shares of the company’s stock after buying an additional 355 shares during the period. Eli Lilly and Company comprises about 0.8% of Harvest Fund Management Co. Ltd’s portfolio, making the stock its 22nd largest holding. Harvest Fund Management Co. Ltd’s holdings in Eli Lilly and Company were worth $5,368,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Madison Park Capital Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $325,000. Schnieders Capital Management LLC increased its stake in shares of Eli Lilly and Company by 5.8% in the 4th quarter. Schnieders Capital Management LLC now owns 6,224 shares of the company’s stock valued at $3,628,000 after purchasing an additional 342 shares in the last quarter. NewSquare Capital LLC increased its stake in shares of Eli Lilly and Company by 4.9% in the 4th quarter. NewSquare Capital LLC now owns 4,184 shares of the company’s stock valued at $2,439,000 after purchasing an additional 194 shares in the last quarter. GAMMA Investing LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $3,774,000. Finally, Eudaimonia Advisors LLC increased its stake in shares of Eli Lilly and Company by 5.2% in the 4th quarter. Eudaimonia Advisors LLC now owns 2,031 shares of the company’s stock valued at $1,184,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY traded up $14.29 during trading hours on Tuesday, hitting $745.62. The company had a trading volume of 2,041,595 shares, compared to its average volume of 3,051,032. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a 1-year low of $370.68 and a 1-year high of $800.78. The company has a market cap of $708.46 billion, a PE ratio of 128.56, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34. The business has a 50 day moving average of $763.89 and a 200-day moving average of $664.05.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the prior year, the firm posted $2.09 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 28.1% on a year-over-year basis. As a group, equities research analysts expect that Eli Lilly and Company will post 12.52 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Morgan Stanley lifted their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Citigroup boosted their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a report on Monday, April 15th. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $728.05.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the completion of the sale, the insider now owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.